Several research studies have demonstrated the potential use of cerebrospinal fluid biomarkers such as amyloid beta 1-42, T-tau, and P-tau, in early diagnosis of Alzheimer’s disease stages. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.